Table 1:
Baseline Characteristics Characteristics
| Control (n=11) | Psoriasis (n=37) | p-value | |
|---|---|---|---|
|
| |||
| Age, y | 42 (31 – 48) | 44 (34 – 51) | 0.19 |
| Male sex, n (%) | 7 (64) | 18 (49) | 0.38 |
| Body mass index, kg/m2 | 27 (23 – 30) | 27 (24 – 30) | 0.51 |
| Caucasian, n (%) | 6 (55) | 28 (76) | 0.35 |
| Systolic blood pressure (mmHg) | 119 (108 – 133) | 124 (109 – 139) | 0.49 |
| Diastolic blood pressure (mmHg) | 69 (61 – 73) | 73 (68 – 82) | 0.05 |
| ACC/AHA ASCVD Risk Score, % | 0.6 (0.3 – 3.6) | 1 (0.6 – 3.4) | 0.62 |
| Psoriasis | |||
| PASI score | 4.0 (2.9 – 8.2) | ||
| Psoriasis duration, years | 15 (9 – 25) | ||
| Psoriatic arthritis, n (%) | 8 (42) | ||
| Biologic therapy, n (%) | 13 (36) | ||
| Biomarkers | |||
| WBC, × 103 cells/mm3 | 6.3 (4.9 – 6.9) | 6.5 (5.5 – 7.7) | 0.36 |
| hs-CRP, mg/L | 1.1 (0.2 – 1.8) | 1.6 (0.7 – 3.6) | 0.31 |
| IL-17A, NPX | 1.8 (1.2 – 3.0) | 2.7 (1.9 – 4.6) | 0.03 |
| IL-6, NPX | 3.1 (2.7 – 3.7) | 3.4 (3.1 – 4.3) | 0.18 |
| TNF-α, NPX | 3.4 (3.3 – 3.8) | 3.7 (3.3 – 4.1) | 0.28 |